4.1 Cardiopulmonary, Metabolic & Neurological Comorbidities

4.1 Cardiopulmonary, Metabolic & Neurological Comorbidities

Quick Answer: Sleep disorders share profound bidirectional pathophysiological relationships with chronic cardiovascular, metabolic, pulmonary, neurological, and psychiatric diseases. Obstructive sleep apnea (OSA) causes nocturnal sympathetic surges that extinguish the normal 10% to 20% blood pressure dip (non-dipper profile), while heart failure triggers Cheyne-Stokes central breathing. In pulmonary disease, COPD and OSA combine as the Overlap Syndrome, producing severe nocturnal hypoxemia and hypercapnia. Neurologically, sleep-disordered breathing affects most stroke survivors, REM Sleep Behavior Disorder (RBD) serves as a key prodromal herald for Parkinson's disease, and Alzheimer's disease causes profound circadian disintegration. In psychiatric disorders like major depression, sleep architecture features shortened REM latency and elevated REM density.

For the Clinical Sleep Health Specialist (CCSH), sleep pathology cannot be managed in isolation. Systemic, neurological, and psychiatric conditions interact continuously with sleep mechanisms, demanding comprehensive risk assessment and tailored interventions.

Cardiovascular Comorbidities

The cardiovascular system is highly vulnerable to sleep-disordered breathing:

• Hypertension & The Non-Dipper Profile: In healthy adults, blood pressure drops 10% to 20% at night (nocturnal dipping). Untreated OSA causes recurrent apneas ending in arousals and sympathetic surges, producing a non-dipper profile (less than 10% drop) or reverse-dipper profile (nocturnal BP exceeds daytime BP). Non-dipping hypertension sharply elevates stroke and myocardial infarction risks, and in a landmark study 83% of patients with drug-resistant hypertension had OSA.
• Coronary Artery Disease & Heart Failure: Repetitive hypoxemia and extreme negative intrathoracic pressures (-60 to -80 cmH2O) increase ventricular wall stress and myocardial oxygen demand. In systolic heart failure (HFrEF), prolonged circulation time and hyperventilation drive PaCO2 below the apneic threshold, causing Cheyne-Stokes Respiration (CSR) with central apneas.
  • ASV safety signal: In the SERVE-HF trial (2015), one adaptive servo-ventilation (ASV) device increased cardiovascular and all-cause mortality in heart failure with LVEF ≤45% and predominant central sleep apnea, and that manufacturer's labeling contraindicates this use. The 2024 ADVENT-HF trial of a different ASV algorithm found no such harm, and the AASM's 2025 central sleep apnea guideline conditionally supports ASV but limits its use in heart failure with reduced ejection fraction to experienced centers with close monitoring.
• Atrial Fibrillation (AF): In the Sleep Heart Health Study, severe sleep-disordered breathing carried about four-fold higher odds of AF. Untreated OSA is associated with more AF recurrence after cardioversion or catheter ablation, and observational studies link regular CPAP use with lower recurrence.

Metabolic Comorbidities

Sleep disruption and intermittent hypoxia profoundly impair metabolism:

• Type 2 Diabetes Mellitus (T2DM): Intermittent hypoxia stimulates HIF-1alpha, generating reactive oxygen species and inflammatory cytokines (TNF-alpha, IL-6). Nocturnal cortisol elevations and persistent sympathetic tone worsen peripheral insulin resistance and accelerate pancreatic beta-cell apoptosis.
• Obesity & Metabolic Syndrome: Visceral fat increases pharyngeal collapsibility (elevating critical closing pressure, Pcrit). Concurrently, sleep fragmentation reduces leptin (satiety) and increases ghrelin (hunger), stimulating high-carbohydrate cravings that compound obesity and airway collapse.

Respiratory Comorbidities

• COPD-OSA Overlap Syndrome: The co-occurrence of COPD and OSA affects 10% to 15% of COPD patients. During REM sleep, physiological loss of accessory muscle tone combined with upper airway obstruction causes severe, prolonged nocturnal hypoxemia and hypercapnia far exceeding either disorder alone. Untreated Overlap Syndrome leads to pulmonary hypertension, cor pulmonale, and respiratory failure. Supplemental oxygen alone without PAP is dangerous because it can suppress hypoxic ventilatory drive and worsen hypercapnia; CPAP or Bilevel PAP is the treatment of choice.
• Nocturnal Asthma: Asthmatic symptoms peak between 3:00 AM and 5:00 AM, driven by circadian declines in cortisol and epinephrine, increased vagal bronchoconstrictor tone, and gastroesophageal reflux exacerbated by negative intrathoracic pressures during obstructive events.

Neurological Comorbidities

• Cerebrovascular Disease (Stroke): Meta-analyses find sleep-disordered breathing (AHI >5) in roughly 70% of patients after stroke or TIA. Hypoxia and swings in cerebral blood flow may slow recovery, and untreated sleep apnea is associated with higher rates of recurrent stroke and death.
• Epilepsy: Sleep deprivation lowers seizure thresholds. Interictal epileptiform discharges peak during Stage N2 and N3 NREM sleep due to synchronized thalamocortical firing, whereas REM sleep suppresses seizure spread through cortical desynchronization and atonia. Sleep-Related Hypermotor Epilepsy (SHE) features brief, stereotyped motor attacks out of NREM that must be differentiated from parasomnias.
• Neurodegenerative Disorders:
  • Alzheimer's Disease (AD): SCN degeneration causes circadian rhythm breakdown, sleep fragmentation, and sundowning (late afternoon agitation). Animal studies show the brain's glymphatic system clears beta-amyloid more efficiently during sleep, and human studies link short or fragmented sleep with greater amyloid burden, although cause and effect are still being studied.
  • Parkinson's Disease (PD) & RBD: Degeneration of pontine sleep centers leads to severe sleep fragmentation and REM Sleep Behavior Disorder (RBD), characterized by loss of normal REM muscle atonia and violent dream enactment. Most people with isolated (idiopathic) RBD eventually develop an alpha-synucleinopathy (PD, dementia with Lewy bodies, multiple system atrophy); a 2019 multicenter study found about 74% had converted within 12 years, and RBD can precede motor symptoms by a decade or more.

Psychiatric Comorbidities

• Major Depressive Disorder (MDD): Polysomnography reveals shortened REM latency (less than 60 minutes), increased REM density in the first third of the night, decreased Stage N3 slow-wave sleep, and terminal insomnia (early morning awakenings).
• Generalized Anxiety Disorder (GAD): Elevated sympathetic tone causes prolonged sleep-onset latency, reduced sleep efficiency, and nocturnal panic awakenings.
• Post-Traumatic Stress Disorder (PTSD): Autonomic hyperarousal causes trauma-related nightmares during both REM and NREM sleep; prazosin (an alpha-1 adrenergic antagonist) is used clinically to reduce nightmare frequency.

Clinical Reference Table